Showing 4781-4790 of 20470 results for "".
- Asundexian in Secondary Stroke Prevention After Noncardioembolic Eventshttps://reachmd.com/news/asundexian-in-secondary-stroke-prevention-after-noncardioembolic-events/2486837/Key Takeaways Asundexian was associated with a lower risk of ischemic stroke versus placebo in patients with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack. The randomized phase 3 comparison evaluated efficacy outcomes a
- Prehospital Opioid Dosing and Downstream Outcomes in Older Adultshttps://reachmd.com/news/prehospital-opioid-dosing-and-downstream-outcomes-in-older-adults/2486824/Key Takeaways Older adults who received EMS-administered opioid analgesics before arrival were evaluated in a retrospective cohort study. Emergency department and hospital outcomes after that prehospital exposure were assessed, including specific safet
- Aflibercept 8 Mg in DME: 96-Week PHOTON Resultshttps://reachmd.com/news/aflibercept-8-mg-in-dme-96-week-photon-results/2486828/Key Takeaways At week 96, best-corrected visual acuity gains and central retinal thickness reductions were comparable across the aflibercept 8 mg extended-interval groups and the aflibercept 2 mg every-8-week group. Fewer active injections were observe
- Extended-Release vs Sublingual Buprenorphine in Pregnancy and Postpartumhttps://reachmd.com/news/extended-release-vs-sublingual-buprenorphine-in-pregnancy-and-postpartum/2486841/Key Takeaways Extended-release buprenorphine was associated with higher illicit opioid abstinence during pregnancy. Abstinence declined postpartum and appeared similar in the two treatment groups. Serious adverse events were less frequent with
- BPO Not Linked with Higher Malignancy Risk: Meta-analysishttps://reachmd.com/news/bpo-not-linked-with-higher-malignancy-risk-meta-analysis/2486846/Benzoyl peroxide (BPO) use for acne vulgaris was not significantly associated with increased malignancy risk in a systematic review and meta-analysis of more than 4 million patients, accoriding to results from a new meta-analysis.
- Locus Coeruleus TDP-43 Pathology in Aging Cohorthttps://reachmd.com/news/locus-coeruleus-tdp-43-pathology-in-aging-cohort/2486826/Key Takeaways LC pTDP-43 appeared in about one-fifth of brains and was generally sparse when detected. Prevalence increased with age and higher LATE-NC stage, but alignment was incomplete and did not mirror cortical pTau burden in ADNC or PART.
- LB-102 Shows Phase 2 Efficacy and Short-Term Safety in Schizophreniahttps://reachmd.com/news/lb-102-shows-phase-2-efficacy-and-short-term-safety-in-schizophrenia/2486843/Key Takeaways LB-102 50 mg and 75 mg were superior to placebo on week 4 PANSS total score change, and 100 mg was nominally significant. CGI-S and PANSS positive symptom measures improved across doses, several Marder factor scores moved in the same dire
- SMART Study Compares Staged Nonpharmacologic Care for Chronic Low Back Painhttps://reachmd.com/news/smart-study-compares-staged-nonpharmacologic-care-for-chronic-low-back-pain/2486811/Key Takeaways Physical therapy was associated with an early functional advantage over cognitive behavioral therapy at 10 weeks. Pain intensity did not differ at 10 weeks, and no stage II strategy separated from another at 52 weeks among nonresponders.<
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://reachmd.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- SkinCeuticals Launches Future Mineral UV Defense SPF 50 for Daily and Post-Procedure Usehttps://reachmd.com/news/skinceuticals-launches-future-mineral-uv-defense-spf-50-for-daily-and-post-procedure-use/2486804/SkinCeuticals has introduced Future Mineral UV Defense SPF 50, a new mineral sunscreen designed to provide broad-spectrum UV protection while also addressing visible signs of skin aging, according to the company. The formulation combines 15% zinc oxide and 3% titanium dioxide and is intend